Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study.
Yukio HosomiTakashi SetoMakoto NishioKoichi GotoNoboru YamamotoIsamu OkamotoKosei TajimaYusuke KajiharaNobuyuki YamamotoPublished in: Thoracic cancer (2022)
Erlotinib plus bevacizumab may be a beneficial treatment strategy in patients with EGFR+ NSCLC, especially for those with baseline PPE.